[Evaluation of the serum lysozyme level as a further parameter for predicting hematological tolerance in patients treated with cytostatic chemotherapy. Study of 134 cases].
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy; D001943:Breast Neoplasms / Q000188:drug therapy; D004361:Drug Tolerance; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy; D006098:Granulocytes; D006410:Hematopoiesis / Q000187:drug effects; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D009113:Muramidase / Q000097:blood*; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D009113:Muramidase
Valutazione del tasso di lisozima serico come ulteriore parametro per la previsione della tolleranza ematologica in malati sottoposti a chemioterapia citostatica. Studio di 134 casi.